Allakos Inc (ALLK)

Dec 19, 2024, 4:15 PM EST - 4 weeks ago

Kuehn Law Encourages Investors of Allakos Inc. to Contact Law Firm

Nov 7, 2024, 5:13 AM EST - 2 months ago

Allakos Runs Up Into A Near-Term Catalyst

Nov 6, 2024, 4:02 PM EST - 2 months ago

Allakos Provides Business Update and Reports Third Quarter 2024 Financial Results

Oct 10, 2024, 4:02 PM EDT - 3 months ago

Allakos Announces Phase 1 Trial Results of Subcutaneous AK006 in Healthy Volunteers

Aug 7, 2024, 4:02 PM EDT - 5 months ago

Allakos Provides Business Update and Reports Second Quarter 2024 Financial Results

Jun 28, 2024, 11:00 AM EDT - 7 months ago

The Schall Law Firm Begins Probe Into Claims Against Allakos Inc And Urges Affected Investors To Participate

Jun 26, 2024, 9:15 PM EDT - 7 months ago

The Schall Law Firm Initiates Investigation Into Allegations Against Allakos Inc And Encourages Impacted Investors To Engage

Jun 25, 2024, 4:02 PM EDT - 7 months ago

Allakos Announces Positive Results from its Ongoing Phase 1 Trial of AK006 in Healthy Volunteers, with AK006 Demonstrating High Receptor Occupancy on Mast Cells and a Favorable Safety Profile

Jun 24, 2024, 6:50 PM EDT - 7 months ago

The Schall Law Firm Initiates Investigation Into Allegations Against Allakos Inc And Encourages Impacted Investors To Join

Jun 23, 2024, 11:00 AM EDT - 7 months ago

The Schall Law Firm Starts Probe Into Claims Against Allakos Inc And Urges Affected Investors To Participate

Jun 22, 2024, 11:00 AM EDT - 7 months ago

The Schall Law Firm Initiates Investigation Into Allegations Against Allakos Inc And Encourages Impacted Investors To Get Involved

Jun 19, 2024, 4:15 PM EDT - 7 months ago

Claims Against Allakos Inc The Schall Law Firm Begins Probe And Urges Affected Investors To Participate

Jun 18, 2024, 4:00 PM EDT - 7 months ago

Allegations Against Allakos Inc The Schall Law Firm Initiates Investigation And Encourages Impacted Investors To Get Involved

Jun 17, 2024, 5:00 PM EDT - 7 months ago

Claims Against Allakos Inc Schall Law Firm Begins Probe And Urges Affected Investors To Participate

Jun 11, 2024, 6:30 PM EDT - 7 months ago

Allegations Against Allakos Inc.: Schall Law Firm Initiates Investigation And Encourages Impacted Investors To Get Involved

Jun 9, 2024, 11:00 AM EDT - 7 months ago

Charges Against Allakos Inc.: Schall Law Firm Launches Examination And Invites Affected Investors To Participate

Jun 8, 2024, 11:00 AM EDT - 7 months ago

Accusations Against Allakos Inc.: Schall Law Firm Begins Inquiry And Calls On Impacted Investors To Engage

Jun 7, 2024, 4:40 PM EDT - 8 months ago

Claims Against Allakos Inc.: Schall Law Firm Initiates Probe And Invites Affected Investors To Connect

Jun 6, 2024, 1:00 PM EDT - 8 months ago

Allegations Against Allakos Inc.: Schall Law Firm Begins Investigation And Encourages Impacted Investors To Reach Out

Jun 5, 2024, 1:45 PM EDT - 8 months ago

Allakos Inc. Allegations: Schall Law Firm Initiates Probe and Invites Affected Investors to Connect

Jun 4, 2024, 3:00 PM EDT - 8 months ago

The Schall Law Firm is Initiating a Probe into Allegations Against Allakos Inc. and Invites Investors who have Suffered losses to Get in Touch

Jun 3, 2024, 4:55 PM EDT - 8 months ago

ALLK IMPORTANT ACTION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Allakos Inc. and Encourages Investors with Losses to Contact the Firm

Jun 2, 2024, 11:00 AM EDT - 8 months ago

IMPORTANT ACTION UPDATE: The Schall Law Firm Announces it is Investigating Claims Against Allakos Inc. and Encourages Investors with Losses to Contact the Firm

May 31, 2024, 6:00 PM EDT - 8 months ago

IMPORTANT ACTION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Allakos Inc. and Encourages Investors with Losses to Contact the Firm

May 28, 2024, 7:02 AM EDT - 8 months ago

Allakos Announces First Patient Dosed in Phase 1 Trial of AK006 in Chronic Spontaneous Urticaria

May 17, 2024, 1:15 PM EDT - 8 months ago

IMPORTANT SHAREHOLDER INVESTIGATION: The Schall Law Firm Announces it is Investigating Claims Against Allakos Inc. and Encourages Investors with Losses to Contact the Firm

May 9, 2024, 4:02 PM EDT - 9 months ago

Allakos Provides Business Update and Reports First Quarter 2024 Financial Results

Mar 14, 2024, 4:02 PM EDT - 11 months ago

Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Feb 26, 2024, 7:02 AM EST - 11 months ago

Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024

Feb 12, 2024, 7:02 AM EST - 1 year ago

Allakos Announces Publication Highlighting AK006 Mast Cell Inhibition

Feb 6, 2024, 4:00 AM EST - 1 year ago

IMPORTANT DEADLINE NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Allakos Inc. and Encourages Investors with Losses to Contact the Firm

Jan 16, 2024, 7:30 AM EST - 1 year ago

Allakos to stop further development of skin disease drug, plans job cuts

Jan 16, 2024, 7:02 AM EST - 1 year ago

Allakos Announces a Restructuring to Focus on Development of AK006

Nov 13, 2023, 4:02 PM EST - 1 year ago

Allakos Provides Business Update and Reports Third Quarter 2023 Financial Results

Sep 18, 2023, 2:07 AM EDT - 1 year ago

Scratching The Surface: Allakos' Novel Take On Urticaria

Aug 30, 2023, 4:05 PM EDT - 1 year ago

Allakos Appoints Neil Graham to its Board of Directors

Aug 21, 2023, 7:32 AM EDT - 1 year ago

Top 5 Health Care Stocks That Could Blast Off This Month - Allakos (NASDAQ:ALLK), BioLife Solns (NASDAQ:BLFS)

BLFS KZR TCRT

Aug 9, 2023, 4:02 PM EDT - 1 year ago

Allakos Provides Business Update and Reports Second Quarter 2023 Financial Results

Aug 2, 2023, 4:05 PM EDT - 1 year ago

Allakos Appoints Rand Sutherland and Dolca Thomas to its Board of Directors

Jun 12, 2023, 7:02 AM EDT - 1 year ago

Allakos Presents Preclinical Data at EAACI Hybrid Congress 2023 Highlighting Lirentelimab and AK006 Mechanisms of Mast Cell Inhibition

Jun 5, 2023, 7:02 AM EDT - 1 year ago

Allakos Announces Upcoming Presentation on Lirentelimab and AK006 Mast Cell Inhibition at the European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2023

May 21, 2023, 9:23 AM EDT - 1 year ago

May MDA Breakout Stocks/ETFs Week 21 - 2023: High-Frequency Gainers To Give You An Edge

ANNX EHTH FLNC

May 9, 2023, 4:02 PM EDT - 1 year ago

Allakos Provides Business Update and Reports First Quarter 2023 Financial Results